KalVista Pharmaceuticals, Inc. (KALV)
Automate Your Wheel Strategy on KALV
With Tiblio's Option Bot, you can configure your own wheel strategy including KALV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KALV
- Rev/Share 0.0
- Book/Share 2.9228
- PB 5.2073
- Debt/Equity 0.0398
- CurrentRatio 10.4376
- ROIC -0.7606
- MktCap 760295314.0
- FreeCF/Share -2.5862
- PFCF -5.9207
- PE -4.1196
- Debt/Assets 0.0209
- DivYield 0
- ROE -1.1143
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | KALV | JMP Securities | -- | Mkt Outperform | -- | $19 | Jan. 31, 2025 |
| Initiation | KALV | TD Cowen | -- | Buy | -- | $30 | Jan. 7, 2025 |
| Initiation | KALV | BofA Securities | -- | Buy | -- | $22 | Dec. 18, 2024 |
News
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
Read More
KalVista: FDA Approval Of EKTERLY As Oral On-Demand HAE Drug Is Just Beginning
Published: July 08, 2025 by: Seeking Alpha
Sentiment: Positive
FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy, providing a major competitive advantage over injectable options. EKTERLY's convenience and rapid symptom relief position it for strong market adoption, with a $4 billion HAE market opportunity and potential to shift on-demand market share. Global expansion is underway, with seven regulatory submissions, and if approved for these territories, it could increase the amount of revenues that are to be generated.
Read More
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom from June 13–16, 2025. Details are as follows: Friday, June 13 Potential for Sebetralstat to Address Pseudo-allergic Reaction Burden Secondary to Icatibant in HAE (D1.324): Sally L. Hampton, Paul K. Audhya, Michael D.
Read More
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new sebetralstat findings related to time to end of progression of hereditary angioedema (HAE) attacks, and the effectiveness of treatment of attacks considered the most debilitating by patients, mucosal attacks, and attacks that have progressed in severity after a treatment delay. These data were presented at two congresses taking place concurrently: the 14th C1-inhibitor Defic.
Read More
About KalVista Pharmaceuticals, Inc. (KALV)
- IPO Date 2015-04-09
- Website https://www.kalvista.com
- Industry Biotechnology
- CEO Benjamin L. Palleiko
- Employees 150